PHP
IRMD icon

Parkman Healthcare Partners’s iRadimed IRMD Stock Holding History

Parkman Healthcare Partners’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-94,717
Closed -$2.2M – 89
2020
Q2 		$2.2M Sell
94,717
-19,138
-17% -$411K 0.62% 53
2020
Q1 		$2.43M Buy
113,855
+20,355
+22% +$485K 1.13% 31
2019
Q4 		$2.19M Buy
+93,500
New +$2.18M 0.63% 48

Other funds holding IRMD

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

Parkman Healthcare Partners's IRMD Position: Q3 2020 in Review

Parkman Healthcare Partners sold out of iRadimed (IRMD) in Q3 2020, closing a stake of 94,717 shares — an estimated $2.2M sold.

Parkman Healthcare Partners first reported a position in IRMD in Q4 2019 and held it in 3 quarters. The position peaked at $2.43M in Q1 2020. 62 funds tracked by Wall St. Rank hold IRMD as of Q3 2020.

  • Parkman Healthcare Partners reported no remaining iRadimed position as of Q3 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 94,717 iRadimed shares in Q3 2020, an estimated $2.2M.
  • Parkman Healthcare Partners first reported a position in iRadimed in Q4 2019 and held it in 3 quarters.
  • Parkman Healthcare Partners's iRadimed position peaked at $2.43M in Q1 2020.
  • 62 funds tracked by Wall St. Rank held iRadimed as of Q3 2020.

Based on Parkman Healthcare Partners's 13F filing for Q3 2020, filed 13 Nov 2020.